Nanoparticle-based vaginal drug delivery systems for HIV prevention

Expert Opinion on Drug Delivery

Volumn 7, Issue 1, 2010, Pages 37-48

  Mallipeddi, Rama ^a,b   Rohan, Lisa Cencia ^a,b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

HIV prevention; Nanoparticles; Topical microbicides; Vaginal drug delivery

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NANOCAPSULE; NANOCARRIER;

DRUG DELIVERY SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; SEXUAL TRANSMISSION; VAGINA; VAGINA MUCOSA;

ANTI-HIV AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; HIV INFECTIONS; HUMANS; NANOPARTICLES; VAGINA;

EID: 73649121308     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903338055     Document Type: Review

References (97)

1. Krishnan S, Dunbar MS, Minnis AM, et al. Poverty, gender inequities, and women's risk of human immunodeficiency virus/AIDS. Ann NY Acad Sci 2008;1136:101-110
2. Garg S, Kandarapu R, Vermani K, et al. Development pharmaceutics of microbicide formulations. Part I: preformulation considerations and challenges. AIDS Patient Care STDS 2003;17(1):17-32 (Pubitemid 36083819)
3. Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 2005;73(6):1253-1263
4. Valenta C. The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev 2005;57(11):1692-1712
5. Stein ZA. HIV prevention: the need for methods women can use. Am J Public Health 1990;80(4):460-462
6. Pauwels R, De Clercq E. Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11(3):211-221
7. Dezzutti CS, Guenthner PC, Cummins JE Jr, et al. Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J Infect Dis 2001;183(8):1204-1213
8. Miller CJ, Shattock RJ. Target cells in vaginal HIV transmission. Microbes Infect 2003;5(1):59-67
9. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003;1(1):25-34
10. Boggiano C, Littman DR. HIV's vagina travelogue. Immunity 2007;26(2):145-147
11. Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 2003;9(7):847-852
12. Kawamura T, Kurtz SE, Blauvelt A, Shimada S. The role of Langerhans cells in the sexual transmission of HIV. J Dermatol Sci 2005;40(3):147-155
13. Kawamura T, Cohen SS, Borris DL, et al. Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med 2000;192(10):1491-1500
14. Hladik F, Hope TJ. HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009;6(1):20-28
15. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004;306(5695):485-487
16. Mayer KH, Karim SA, Kelly C, et al. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 2003;17(3):321-329
17. Rohan LC, Ratner D, McCullough K, et al. Measurement of anti-HIV activity of marketed vaginal products and excipients using a PBMC-based in vitro assay. Sex Transm Dis 2004;31(3):143-148
18. Ham AS, Cost MR, Sassi AB, et al. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res 2009;26(3):502-511
19. Van Herrewege Y, Michiels J, Van Roey J, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004;48(1):337-339
20. Doms RW, Trono D. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev 2000;14(21):2677-2688
21. Marechal V, Prevost MC, Petit C, et al. Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis. J Virol 2001;75(22):11166-11177
22. Pauza CD, Price TM. Human immunodeficiency virus infection of T cells and monocytes proceeds via receptor-mediated endocytosis. J Cell Biol 1988;107(3):959-968
23. Fredericksen BL, Wei BL, Yao J, et al. Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J Virol 2002;76(22):11440-11446
24. Daecke J, Fackler OT, Dittmar MT, Krausslich HG. Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry. J Virol 2005;79(3):1581-1594
25. Miyauchi K, Kim Y, Latinovic O, et al. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 2009;137(3):433-444 The studies in this paper provide evidence that the primary mode of HIV entry is indeed by means of endocytosis.
26. Schmidt C, Lamprecht A. Nanocarriers in Drug Delivery-Design, Manufacture and Physicochemical Properties. In: Lamprecht A, editor, Nanotherapeutics - drug delivery concepts in nanoscience. Singapore: Pan Stanford; 2009. p. 3-37
27. Rodriguez SG, Allemann E, Fessi H, Doelker E. Physicochemical parameters associated with nanoparticles formation in the salting out, emulsification- diffusion and nanoprecipitation methods. Pharm Res 2004;21:1428
28. Narain R, Housni A, Gody G, et al. Preparation of biotinylated glyconanoparticles via a photochemical process and study of their bioconjugation to streptavidin. Langmuir 2007;23(26):12835-12841
29. Quintanar-Guerrero D, Allemann E, Doelker E, Fessi H. Preparation and characterization of nanocapsules from preformed polymers by a new process based on emulsification-diffusion technique. Pharm Res 1998;15(7):1056-1062
30. Quintanar-Guerrero D, Allemann E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm 1998;24(12):1113-1128
31. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000;11(Suppl 2):S81-91
32. Liu Z, Zhong Z, Peng G, et al. Folate receptor mediated intracellular gene delivery using the charge changing solid lipid nanoparticles. Drug Deliv 2009;16(6):341-347
33. Zhang X, Koh CG, Yu B, et al. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model. Pharm Res 2009;26(6):1516-1524
34. Perera G, Greindl M, Palmberger TF, Bernkop-Schnurch A. Insulin-loaded poly (acrylic acid)-cysteine nanoparticles: stability studies towards digestive enzymes of the intestine. Drug Deliv 2009;16(5):254-260
35. Zou W, Cao G, Xi Y, Zhang N. New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles. Drug Deliv 2009;16(1):15-23
36. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 1997;14(10):1431-1436
37. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 2001;47(1):39-54 (Pubitemid 32209231)
38. Liu Y, Franzen S. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles. Bioconjug Chem 2008;19(5):1009-1016
39. Thirawong N, Thongborisute J, Takeuchi H, Sriamornsak P. Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J Control Release 2008;125(3):236-245
40. Kingsley JD, Dou H, Morehead J, et al. Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol 2006;1(3):340-350
41. Langer R. Drug delivery and targeting. Nature 1998;392(Suppl 6679):5-10
42. Yoo HS, Oh JE, Lee KH, Park TG. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm Res 1999;16(7):1114-1118
43. Kim S, Kwon K, Kwon IC, Park K. Nanotechnology in drug delivery: past, present and future. In: de Villiers MM, Aramwit P, Kwon GS, editors, Nanotechnology in drug delivery. New York: Springer. 2008. p. 581-596
44. Fu K, Harrell R, Zinski K, et al. A potential approach for decreasing the burst effect of protein from PLGA microspheres. J Pharm Sci 2003;92(8):1582-1591
45. Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long-circulating polymeric nanospheres. Science 1994;263(5153):1600-1603
46. Huh KM, Lee SC, Cho YW, et al. Hydrotropic polymer micelle system for delivery of paclitaxel. J Control Release 2005;101(1-3):59-68
47. Owens DE III, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006;307(1):93-102
48. Illum L, Jacobsen LO, Muller RH, et al. Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. Biomaterials 1987;8(2):113-117
49. Frank MM, Fries LF. The role of complement in inflammation and phagocytosis. Immunol Today 1991;12(9):322-326
50. Teijeiro-Osorio D, Remunan-Lopez C, Alonso MJ. New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules. Biomacromolecules 2009;10(2):243-249
51. Wang X, Zheng C, Wu Z, et al. Chitosan-NAC nanoparticles as a vehicle for nasal absorption enhancement of insulin. J Biomed Mater Res B Appl Biomater 2009;88(1):150-161
52. Kim DH, Martin DC. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials 2006;27(15):3031-3037
53. Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target 2009;17(8):564-574
54. Rezayat SM, Boushehri SV, Salmanian B, et al. The porphyrin-fullerene nanoparticles to promote the ATP overproduction in myocardium: 25Mg2+-magnetic isotope effect. Eur J Med Chem 2009;44(4):1554-1569
55. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56(11):1649-1659
56. Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003;42(5):439-462
57. Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev 2009;61(2):140-157
58. Illum L, Jabbal-Gill I, Hinchcliffe M, et al. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001;51(1-3):81-96
59. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009;61(2):158-171
60. Mrsny RJ. Lessons from nature: "Pathogen-Mimetic" systems for mucosal nano-medicines. Adv Drug Deliv Rev 2009;61(2):172-192
61. Utech M, Bruwer M, Nusrat A. Tight junctions and cell-cell interactions. Methods Mol Biol 2006;341:185-195
62. Dyer AM, Hinchcliffe M, Watts P, et al. Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res 2002;19(7):998-1008
63. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, et al. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res 1999;16(10):1576-1581
64. Teijeiro-Osorio D, Remunan-Lopez C, Alonso MJ. Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro. Eur J Pharm Biopharm 2009;71(2):257-263
65. Mostov K, Su T, ter Beest M. Polarized epithelial membrane traffic: conservation and plasticity. Nat Cell Biol 2003;5(4):287-293 (Pubitemid 36432292)
66. Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev 2009;61(2):75-85
67. Lai SK, Wang YY, Wirtz D, Hanes J. Micro- and macrorheology of mucus. Adv Drug Deliv Rev 2009;61(2):86-100
68. Lai SK, O'Hanlon DE, Harrold S, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci USA 2007;104(5):1482-1487
69. Wickstrom C, Davies JR, Eriksen GV, et al. MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage. Biochem J 1998;334(Pt 3):685-693
70. Lai SK, Wang YY, Cone R, et al. Altering mucus rheology to "solidify" human mucus at the nanoscale. PLoS One 2009;4(1):e4294
71. Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev 2005;57(11):1556-1568
72. Liu X, Howard KA, Dong M, et al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 2007;28(6):1280-1288
73. Sarmento B, Ribeiro A, Veiga F, et al. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 2007;24(12):2198-2206
74. Rekha MR, Sharma CP. Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption. J Control Release 2009;135(2):144-151
75. Cui F, Qian F, Yin C. Preparation and characterization of mucoadhesive polymer-coated nanoparticles. Int J Pharm 2006;316(1-2):154-161
76. Kawashima Y, Yamamoto H, Takeuchi H, Kuno Y. Mucoadhesive DL-lactide/ glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm Dev Technol 2000;5(1):77-85
77. Bernkop-Schnurch A. Mucoadhesive polymers: strategies, achievements and future challenges. Adv Drug Deliv Rev 2005;57(11):1553-1555
78. Galindo-Rodriguez SA, Allemann E, Fessi H, Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit Rev Ther Drug Carrier Syst 2005;22(5):419-464
79. Lehr CM, Bouwstra JA, Kok W, et al. Bioadhesion by means of specific binding of tomato lectin. Pharm Res 1992;9(4):547-553
80. Montisci MJ, Dembri A, Giovannuci G, et al. Gastrointestinal transit and mucoadhesion of colloidal suspensions of Lycopersicon esculentum L. and Lotus tetragonolobus lectin-PLA microsphere conjugates in rats. Pharm Res 2001;18(6):829-837
81. Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Paediatr Respir Rev 2007;8(1):24-29
82. Dawson M, Krauland E, Wirtz D, Hanes J. Transport of polymeric nanoparticle gene carriers in gastric mucus. Biotechnol Prog 2004;20(3):851-857
83. Sanders NN, De Smedt SC, Van Rompaey E, et al. Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am J Respir Crit Care Med 2000;162(5):1905-1911
84. Rubin BK, Kater AP, Goldstein AL. Thymosin beta4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro. Chest 2006;130(5):1433-1440
85. Olmsted SS, Padgett JL, Yudin AI, et al. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J 2001;81(4):1930-1937
86. Dawson M, Wirtz D, Hanes J. Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J Biol Chem 2003;278(50):50393-50401
87. Sherwood JK, Zeitlin L, Whaley KJ, et al. Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes. Nat Biotechnol 1996;14(4):468-471
88. Barnhart K, Shalaby W. The Vagina: physiologic characteristics important to formulators of microbicides. In: Rencher WF, editor, Vaginal microbicide formulation workshop. 1st edition. Philadelphia: Lippincott-Raven; 1998. p. 1-15
89. Treves C, Vincenzini MT, Vanni P, et al. Changes in enzyme levels in human cervical mucus during the menstrual cycle. Int J Fertil 1986;31(1):59-66
90. Schumacher GF. Biochemistry of cervical mucus. Fertil Steril 1970;21(10):697-705
91. He Q, Mitchell A, Morcol T, Bell SJ. Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin Diagn Lab Immunol 2002;9(5):1021-1024
92. Woodrow KA, Cu Y, Booth CJ, et al. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 2009;8(6):526-533
93. Ballagh SA, Baker JM, Henry DM, Archer DF. Safety of single daily use for one week of C31G HEC gel in women. Contraception 2002;66(5):369-375
94. Kreiss J, Ngugi E, Holmes K, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992;268(4):477-482
95. Mauck CK, Ballagh SA, Creinin MD, et al. Six-day randomized safety trial of intravaginal lime juice. J Acquir Immune Defic Syndr 2008;49(3):243-250
96. Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998;339(8):504-510
97. Zekeng L, Feldblum PJ, Oliver RM, Kaptue L. Barrier contraceptive use and HIV infection among high-risk women in Cameroon. AIDS 1993;7(5):725-731